A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

Name: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Creator: Vivli
Published: 2025-02-10 13:14:05
License: 暂无描述

DataCite Commons2025-02-10 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00010556/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

提供机构：

Vivli

创建时间：

2024-10-09